RLIP76 GENE VARIANTS ARE NOT ASSOCIATED WITH
DRUG RESPONSE IN TURKISH EPILEPSY PATIENTS
Manguoğlu E1,*, Akdeniz S1, Dündar NO2, Duman Ö2,
Aktekin B3, Haspolat Ş2, Bilge U4, Özel D4, Lüleci G1
*Corresponding Author: Esra Manguoğlu, Department of Medical Biology and Genetics, Faculty of Medicine,
Akdeniz University, Antalya, Turkey;
Tel.: +90-242-249-6977; Fax: +90-242-249-6906; E-mail: emanguoglu@akdeniz.edu.tr
page: 25
|
|
REFERENCES
1. Sillanpää M, Schmidt D. Natural history of treated
childhood-onset epilepsy: prospective, long-term population-
based study. Brain. 2006; 129(Pt. 3): 617-624.
2. Steinlein OK. Gene polymorphisms and their role in
epilepsy treatment and prognosis. Naunyn Schmiedebergs
Arch Pharmacol. 2010; 382(2): 109-118.
3. Sisodiya SM, Marini C. Genetics of antiepileptic drug
resistance. Curr Opin Neurol. 2009; 22(2): 150-156.
4. Awasthi S, Hallene KL, Fazio V, Singhal SS, Cucullo
L, Awasthi YC, Dini G, Janigro D. RLIP76, a non-ABC
transporter, and drug resistance in epilepsy. BMC Neurosci.
2005; 6: 61.
5. Jullien-Flores V, Dorseuil O, Romero F, Letourneur F,
Saragosti S, Berger R, Tavitian A, Gacon G, Camonis
JH. Bridging Ral GTPase to Rho pathways. RLIP76, a
Ral effector with CDC42/Rac GTPase-activating protein
activity. J Biol Chem. 1995; 270(38): 22473-22477.
6. Awasthi S, Singhal SS, Sharma R, Zimniak P, Awasthi
YC. Transport of glutathione conjugates and chemotherapeutic
drugs by RLIP76 (RALBP1): a novel link
between G-protein and tyrosine kinase signaling and
drug resistance. Int J Cancer. 2003; 106(5): 635-646.
7. Sharma R, Singhal SS, Cheng J, Yang Y, Sharma A,
Zimniak P, Awasthi S, Awasthi YC. RLIP76 is the major
ATP-dependent transporter of glutathione-conjugates
and doxorubicin in human erythrocytes. Arch Biochem
Biophys. 2001; 391(2): 171-179.
8. Rossé C, L’Hoste S, Offner N, Picard A, Camonis J.
RLIP, an effector of the Ral GTPases, is a platform for
Cdk1 to phosphorylate epsin during the switch off of
endocytosis in mitosis. J Biol Chem. 2003; 278(33):
30597-30604.
9. Singhal SS, Yadav S, Singhal J, Awasthi YC, Awasthi S.
Mitogenic and drug-resistance mediating effects of PKCalpha
require RLIP76. Biochem Biophys Res Commun.
2006; 348(2): 722-727.
10. Awasthi S, Singhal SS, Yadav S, Singhal J, Vatsyayan
R, Zajac E, Luchowski R, Borvak J, Gryczynski K,
Awasthi YC. A central role of RLIP76 in regulation of
glycemic control. Diabetes. 2010; 59(3): 714-725.
11. Soranzo N, Kelly L, Martinian L, Burley MW, Thom
M, Sali A, Kroetz DL, Goldstein DB, Sisodiya SM.
Lack of support for a role for RLIP76 (RALBP1) in
response to treatment or predisposition to epilepsy. Epilepsia.
2007; 48(6): 674-683.
12. Leschziner GD, Jorgensen AL, Andrew T, Williamson
PR, Marson AG, Coffey AJ, Middleditch C, Balding
DJ, Rogers J, Bentley DR, Chadwick D, Johnson MR,
Pirmohamed M. The association between polymorphisms
in RLIP76 and drug response in epilepsy. Pharmacogenomics.
2007; 8(12): 1715-1722.
13. Miller SA, Dykes DD, Polesky HF. A simple salting out
procedure for extracting DNA from human nucleated
cells. Nucleic Acids Res. 1988; 16(3): 1215.
14. Alper OM, Erengin H, Manguoğlu AE, Bilgen T, Cetin
Z, Dedeoğlu N, Lüleci G. Consanguineous marriages
in the province of Antalya, Turkey. Ann Genet. 2004;
47(2): 129-138.
15. Janigro D, Awasthi S, Awasthi YC, Sharma R, Yadav
S, Singhal SS, Hallene K. RLIP76 in AED drug resistance.
Epilepsia. 2007; 48(6): 1218-1219.
16. Sisodiya S, Thom M. Response to Janigro et al. Epilepsia.
2007; 48(6): 219-220.
17. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical
impact of pharmacogenetics on the treatment of epilepsy.
Epilepsia. 2009; 50(1): 1-23.
18. Haerian BS, Roslan H, Raymond AA, Tan CT, Lim KS,
Zulkifli SZ, Mohamed EH, Tan HJ, Mohamed Z. ABCB1
C3435T polymorphism and the risk of resistance
to antiepileptic drugs in epilepsy: a systematic review
and meta-analysis. Seizure. 2010; 19(6): 339-346.
19. Zhang C, Kwan P, Zuo Z, Baum L. In vitro concentration
dependent transport of phenytoin and phenobarbital,
but not ethosuximide, by human P-glycoprotein.
Life Sci. 2010; 86(23-24): 899-905.
20. Rivers F, O’Brien TJ, Callaghan R. Exploring the possible
interaction between antiepilepsy drugs and multidrug
efflux pumps; in vitro observations. Eur J Pharmacol.
2008; 598(1-3): 1-8.
21. Luna-Tortós C, Fedrowitz M, Löscher W. Evaluation
of transport of common antiepileptic drugs by human
multidrug resistance-associated proteins (MRP1, 2 and
5) that are overexpressed in pharmacoresistant epilepsy.
Neuropharmacology. 2010; 58(7): 1019-1032.
22. Sánchez MB, Herranz JL, Leno C, Arteaga R, Oterino
A, Valdizán EM, Nicolás JM, Adín J, Armijo JA. Genetic
factors associated with drug-resistance of epilepsy:
relevance of stratification by patient age and aetiology
of epilepsy. Seizure. 2010; 19(2): 93-101.
23. Berg AT. Identification of pharmacoresistant epilepsy.
Neurol Clin. 2009; 27(4): 1003-1013.
24. Viteva EI, Zahariev ZI. Pseudoresistance in patients
with epilepsy characteristics and determining factors.
Folia Med (Plovdiv). 2009; 51(2): 33-39.
25. Kim WJ, Lee JH, Yi J, Cho YJ, Heo K, Lee SH, Kim
SW, Kim MK, Kim KH, Lee BI, Lee MG. A nonsynonymous
variation in MRP2/ABCC2 is associated with
neurological adverse drug reactions of carbamazepine
in patients with epilepsy. Pharmacogenet Genom. 2010;
20(4): 249-256.
26. Canevini MP, De Sarro G, Galimberti CA, Gatti G, Licchetta
L, Malerba A, Muscas G, La Neve A, Striano P,
Perucca E, and the SOPHIE Study Group. Relationship
between adverse effects of antiepileptic drugs, number
of coprescribed drugs, and drug load in a large cohort
of consecutive patients with drug-refractory epilepsy.
Epilepsia. 2010; 51(5): 797-804.
|
|
|
|
 |
Number 27
VOL. 27 (2), 2024 |
Number 27
VOL. 27 (1), 2024 |
Number 26
Number 26 VOL. 26(2), 2023 All in one |
Number 26
VOL. 26(2), 2023 |
Number 26
VOL. 26, 2023 Supplement |
Number 26
VOL. 26(1), 2023 |
Number 25
VOL. 25(2), 2022 |
Number 25
VOL. 25 (1), 2022 |
Number 24
VOL. 24(2), 2021 |
Number 24
VOL. 24(1), 2021 |
Number 23
VOL. 23(2), 2020 |
Number 22
VOL. 22(2), 2019 |
Number 22
VOL. 22(1), 2019 |
Number 22
VOL. 22, 2019 Supplement |
Number 21
VOL. 21(2), 2018 |
Number 21
VOL. 21 (1), 2018 |
Number 21
VOL. 21, 2018 Supplement |
Number 20
VOL. 20 (2), 2017 |
Number 20
VOL. 20 (1), 2017 |
Number 19
VOL. 19 (2), 2016 |
Number 19
VOL. 19 (1), 2016 |
Number 18
VOL. 18 (2), 2015 |
Number 18
VOL. 18 (1), 2015 |
Number 17
VOL. 17 (2), 2014 |
Number 17
VOL. 17 (1), 2014 |
Number 16
VOL. 16 (2), 2013 |
Number 16
VOL. 16 (1), 2013 |
Number 15
VOL. 15 (2), 2012 |
Number 15
VOL. 15, 2012 Supplement |
Number 15
Vol. 15 (1), 2012 |
Number 14
14 - Vol. 14 (2), 2011 |
Number 14
The 9th Balkan Congress of Medical Genetics |
Number 14
14 - Vol. 14 (1), 2011 |
Number 13
Vol. 13 (2), 2010 |
Number 13
Vol.13 (1), 2010 |
Number 12
Vol.12 (2), 2009 |
Number 12
Vol.12 (1), 2009 |
Number 11
Vol.11 (2),2008 |
Number 11
Vol.11 (1),2008 |
Number 10
Vol.10 (2), 2007 |
Number 10
10 (1),2007 |
Number 9
1&2, 2006 |
Number 9
3&4, 2006 |
Number 8
1&2, 2005 |
Number 8
3&4, 2004 |
Number 7
1&2, 2004 |
Number 6
3&4, 2003 |
Number 6
1&2, 2003 |
Number 5
3&4, 2002 |
Number 5
1&2, 2002 |
Number 4
Vol.3 (4), 2000 |
Number 4
Vol.2 (4), 1999 |
Number 4
Vol.1 (4), 1998 |
Number 4
3&4, 2001 |
Number 4
1&2, 2001 |
Number 3
Vol.3 (3), 2000 |
Number 3
Vol.2 (3), 1999 |
Number 3
Vol.1 (3), 1998 |
Number 2
Vol.3(2), 2000 |
Number 2
Vol.1 (2), 1998 |
Number 2
Vol.2 (2), 1999 |
Number 1
Vol.3 (1), 2000 |
Number 1
Vol.2 (1), 1999 |
Number 1
Vol.1 (1), 1998 |
|
|
